Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting ...Middle East

- Two presentations on the Phase 2b clinical trial show CSF-1 met the primary endpoints and achieved statistically significant and clinically meaningful improvements in distance-corrected near visual acuity (DCNVA) for participants with presbyopia - Presbyopia is the loss of ability to...

Hence then, the article about orasis pharmaceuticals announces phase 2b trial efficacy and safety results of novel presbyopia eye drop candidate csf 1 at the 2022 american society of cataract and refractive surgery ascrs annual meeting was published today ( Saturday 23/04/2022 - 03:42 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Orasis Pharmaceuticals Announces Phase 2b Trial Efficacy and Safety Results of Novel Presbyopia Eye Drop Candidate, CSF-1, at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting )

Also on site :

• 2010s Rock Band Announces Tour for 10th Anniversary of Debut Album
• Nuclear neighbors and a two‑front threat: Why India needs a rocket force
• Russia-Ukraine war: List of key events, day 1,431